This study is not yet accepting patients

A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome

a study on Short Bowel Syndrome Necrotizing Enterocolitis

Summary

Eligibility
for people ages 12 months to 21 years (full criteria)
Location
at UCSF
Dates
study started
study ends around
Principal Investigator
by Matthew Lin, MD (ucsf)
Headshot of Matthew Lin
Matthew Lin

Description

Summary

A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients with Short Bowel Syndrome

Details

This clinical investigation is a study to evaluate safety and probable benefit of the Eclipse XL1 System in pediatric and adult subjects with short bowel syndrome. This study is a single arm study and will enroll subjects ages 12 months to 21 years old at up to 10 study sites in the United States. This study will be open label; treatment allocation will be known by the subjects, the Principal Investigator and his medical staff. Recruitment is expected to occur over the course of 24-36 months.

Device placement will be administered during a standalone procedure or a previously planned procedure that is otherwise needed by the study subject. Subjects may receive up to 2 devices at one time and/or have multiple procedures over time based on clinical necessity Study objectives will be monitored by reviewing patient nutrition, weight, and stool assessment data. The study device will also monitored by radiographic examination to confirm location of the device and assess the safety and probable benefit of distraction enterogenesis until the device is removed or passes out of the intestine naturally. Patients will be followed while the study device is in situ and at 3 and 6 months post device passing or removal. Subjects may or may not be discharged from the hospital while participating in the study, and investigators may recommend that a subject stay in-patient for a portion or the entire length of study, depending on subject health.

Keywords

Short Bowel Syndrome, intestinal failure, Necrotizing enterocolitis, short gut, intestinal volvulus, intestinal atresia, Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome

Eligibility

You can join if…

Open to people ages 12 months to 21 years

  • Subject has short bowel syndrome, defined as 50% or less of expected bowel length based on subject age and/or height, and measured at the time of the subject's prior intestinal resection.
  • Minimum residual bowel length of 10 cm.
  • Male or female patients aged 12 mo to 21 years inclusive
  • The subject, parent or legal guardian of the subject is able to read, understand, and is willing to provide informed consent.
  • The subject or parent or legal guardian of the patient is able to understand the requirements of the study and is willing to bring the subject to all clinic visits and complete all study related procedures (as determined by the investigator).

You CAN'T join if...

  • Ultra-short bowel syndrome defined as less than 10 cm of bowel length.
  • Diagnosed Inflammatory bowel disease-unclassified (not Crohn's or ulcerative colitis)
  • Evidence of active or prior Crohn's disease.
  • Primary intestinal failure (i.e., without loss or resection of intestinal tissue).
  • Coagulopathy, as defined by INR > 1.4 or platelets < 100.
  • Known immunocompromised status including, but not limited to, individuals who have undergone organ transplantation, chemotherapy or radiotherapy within the past 12 months, who have clinically significant leukopenia, who are positive for the human immunodeficiency virus (HIV) or whose immune status makes the subject a poor candidate for clinical trial participation in the opinion of the Investigator.
  • Subject is determined by the investigator to be unsuitable for participation in this trial for any reason.

Locations

  • University of California San Francisco
    San Francisco 5391959 California 5332921 94143 United States
  • Stanford University School of Medicine
    Stanford 5398563 California 5332921 94304 United States
  • Cincinnati Children's Hospital
    Cincinnati 4508722 Ohio 5165418 45229-3026 United States
  • Boston Children's Hospital
    Boston 4930956 Massachusetts 6254926 02115 United States

Lead Scientist at University of California Health

  • Matthew Lin, MD (ucsf)
    Professor, Surgery, School of Medicine. Authored (or co-authored) 31 research publications

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Eclipse Regenesis, Inc.
ID
NCT05535361
Study Type
Interventional
Participants
Expecting 40 study participants
Last Updated